Pharmaceutical Business Review
AUGUST 28, 2023
These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. As part of the contract, Allucent will initiate a Phase IIb clinical trial of 10,000 participants under BARDA’s Clinical Studies Network.
pharmaphorum
OCTOBER 18, 2021
The development of COVID-19 vaccines required levels of cooperation and pioneering science comparable to the Apollo space programme. Within 12 months of the outbreak, vaccines were being deployed to prevent severe infections, hospitalisation, and death. billion people have been fully vaccinated. COVID-19 vaccine tracker.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 16, 2022
Novel therapeutics and vaccines for malaria. This year saw great progress towards making new therapeutics for malaria available sooner rather than later, says Karen Barnes, PhD, professor at the University of Cape Town’s Division of Clinical Pharmacology. Pyramax was codeveloped by MMV and the South Korean company Shin Poong.
pharmaphorum
NOVEMBER 4, 2020
The picture is hardly more promising for vaccines: the number of approaches, difficulty in finding patients in which to carry out pivotal trials, irrelevant choice of endpoints … the outlook is far from promising. The M&S approach should be integrative, from the molecular level to the clinical and population outcomes.
Eye on FDA
AUGUST 4, 2021
FDA has had its reputation tested not only by that decision but by the events of the past few years that called into question a possible politicization of the process and all of the misinformation around COVID-19 and vaccinations. The most active of these committees with vacancies this year has been the Oncologic Drugs Advisory Committee.
pharmaphorum
AUGUST 16, 2022
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. .
Eye on FDA
JANUARY 5, 2022
Of note, this tally does not include meetings of the Vaccines and Related Biologic Products Advisory Committee held to consider a recommendation for COVID-19 vaccines, but includes only drugs and biologics. FDA Adcomms have been declining in number even as the agency approves more drugs.
Expert insights. Personalized for you.
52 
Let's personalize your content